Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sufang Zhou has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Jifei Chen

    Acute Respiratory Infectious Diseases Network Laboratory, Department of Science and Education, GCP Institutional Office, Biobank of Guangxi Chest Hospital, Liuzhou, China

    1 shared publication
  • Liuyan Chen

    State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, China

    1 shared publication
  • Shan Lu

    Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China

    1 shared publication
  • Shuai Li

    Key Laboratory of Biological Molecular Medicine Research, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China

    1 shared publication
  • Yanping Ning

    Department of lmmunology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, China

    1 shared publication
  • Yaobin Wang

    Key Laboratory of Biological Molecular Medicine Research, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China

    1 shared publication

Latest Publications

  • Open Access

    Metabolic syndrome-related gene signature for prognosis and immune microenvironment prediction in hepatocellular carcinoma

    by Liuyan Chen, Yaobin Wang, Shuai Li, Shan Lu, Yiling Luo, Yanping Ning, Jifei Chen, Sufang Zhou

    Metabolic syndrome is a major risk factor for hepatocellular carcinoma (HCC) progression, yet the role of metabolic syndrome-related genes in HCC remains incompletely understood. Using bioinformatics approaches, we investigated the influence of these genes on HCC prognosis and tumor biology. Two distinct patient clusters (C1 and C2) were identified based on metabolic gene expression, with C2 exhibiting poorer survival, increased stemness, and higher risk scores. A risk model further revealed that high-risk patients had worse outcomes, elevated immunosuppressive cell infiltration, and distinct phenotypic features. Experimental validation via qRT-PCR confirmed upregulation of risk model genes (particularly KIAA1841 and TUBA1B) in HCC cell lines and patient blood samples. Notably, post-surgical declines in KIAA1841 and TUBA1B levels were observed. Our findings highlight the clinical relevance of metabolic syndrome-related genes in HCC, linking them to prognosis, tumor microenvironment remodeling, cancer stemness, and immunotherapy response.